Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HANGZHOU TIGERMED CONSULTING CO., LTD.
杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2026 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report of Hangzhou Tigermed Consulting Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") for the financial year 2026. This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 29, 2026

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee director of the Company is Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.

HANGZHOU TIGERMED CONSULTING CO., LTD.

2026 THIRD QUARTERLY REPORT

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and there is no false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The board of directors ("**Directors**") of the Company ("**Board of Directors**"), Directors and senior management warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.

2. The head of the Company, person-in-charge of accounting affairs and head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

3. Whether the third-quarter financial and accounting report is audited

   ☐ Yes ☑ No

I. KEY FINANCIAL DATA

(I) Major accounting data and financial indicators

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

☐Yes ☑No

	Reporting Period	Change	From the beginning of the year to the end of the Reporting Period	Change
Revenue (RMB)	2,083,967,893.14	17.38%	5,791,528,067.34	15.23%
Net profit attributable to shareholders of the listed company (RMB)	141,110,867.04	-77.85%	-272,048,633.37	-126.66%
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss (RMB)	172,345,867.17	49.62%	450,066,412.63	38.08%
Net cash flows from operating activities (RMB)	–	–	771,311,923.45	4.29%
Basic earnings per share (RMB/share)	0.17	-77.14%	-0.32	-126.89%
Diluted earnings per share (RMB/share)	0.17	-77.14%	-0.32	-126.89%
Weighted average return on net assets	0.72%	-2.31%	-1.33%	-6.22%

	End of the Reporting Period	End of prior year	Change
Total assets (RMB)	27,985,815,036.96	28,358,795,158.17	-1.32%
Owners' equity attributable to shareholders of the listed company (RMB)	19,637,700,367.95	20,959,506,514.77	-6.31%

Note: The Reporting Period shall mean a period of three months from the beginning of this third quarter to the end of this third quarter, the same below.

(II) Items and amounts of extraordinary gain or loss

☑Applicable ☐Not applicable

Unit: RMB

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for asset impairment)	2,013,862.66	-16,069,206.08	Mainly due to the disposal of long-term assets such as long-term deferred expenses and right-of-use assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business scope of the Company and entitled in defined standard in conformity with the provisions of policies of the State and that have a sustained impact on the Company's profit or loss) included in the profit or loss for the period	2,324,225.30	27,625,871.36	Mainly due to the government grants received by the Company during the Reporting Period.
Profit or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial companies and profit or loss arising from the disposal of financial assets and financial liabilities (except for those related to effective hedging businesses under ordinary business scope of the Company)	-137,156,205.47	-618,146,484.72	Mainly due to the investment loss recognized from the disposal of non-current financial assets and losses from changes in fair value of other non-current financial assets of the Company during the Reporting Period.

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from investments on trust or asset management	11,178,741.16	32,819,904.18	Mainly due to the income from wealth management products of the Company during the Reporting Period.
Other non-operating income and expenses apart from the above items	-720,052.43	-2,559,220.10	
Less: Effect of income tax	1,309,946.64	35,373,345.20	
Effect of minority interests (after tax)	-92,434,375.29	110,412,565.44	Mainly due to the decrease in the fair value of other non-current financial assets held by the Company's non-wholly-owned subsidiaries during the Reporting Period.
Total	-31,235,000.13	-722,115,046.00	–

Details of other profit or loss items meeting the definition of extraordinary gain or loss:

☐Applicable ☑Not applicable

There were no other profit or loss items that met the definition of extraordinary gain or loss.

Explanation on extraordinary gain or loss items defined as recurring gain or loss items as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss

☐Applicable ☑Not applicable

There was no item of extraordinary gain or loss defined as item of recurring gain or loss as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss.

(III) Changes in key accounting data and financial indicators and the reasons thereof

☑Applicable ☐Not applicable

1. Explanation of anomalies for balance sheet items and the reasons thereof

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Financial assets held for trading	15,454,600.36	59,459,161.12	-74.01%	Mainly due to the maturity of the Company's wealth management products during the Reporting Period.
Receivables financing	816,415.29	3,953,348.43	-79.35%	Mainly due to the maturity of the Company's bank acceptance notes during the Reporting Period.
Advances to suppliers	182,020,443.18	122,972,634.86	48.02%	Mainly due to the increase in prepayments for materials of the Company during the Reporting Period.
Inventories	62,996,166.23	41,501,796.41	51.79%	Mainly due to the Company's procurement of raw materials during the Reporting Period.
Other current assets	194,103,189.19	64,713,930.31	199.94%	Mainly due to the Company's purchase of certificates of deposit during the Reporting Period.
Other non-current assets	1,231,367,406.27	1,979,937,603.41	-37.81%	Mainly due to the maturity of the Company's wealth management products during the Reporting Period.
Short-term borrowings	265,266,196.31	511,020,767.84	-48.09%	Mainly due to the repayment of short-term borrowings by the Company during the Reporting Period.

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Notes payable	3,239,727.72	5,889,386.05	-44.99%	Mainly due to the maturity of the Company's notes payable during the Reporting Period.
Tax payable	112,447,498.78	231,541,815.12	-51.44%	Mainly due to the Company's payment of income tax during the Reporting Period.
Contract liabilities	1,436,359,968.22	1,079,154,504.24	33.10%	Mainly due to the increase in advance payments received by the Company for new orders during the Reporting Period.
Non-current liabilities due within one year	121,268,436.22	201,525,360.57	-39.82%	Mainly due to the repayment of long-term borrowings due within one year by the Company during the Reporting Period.
Long-term borrowings	1,423,866,310.52	510,560,589.95	178.88%	Mainly due to the increase in long-term borrowings of the Company during the Reporting Period.
Long-term payables	11,980,000.00	102,518,850.00	-88.31%	Mainly due to the payment of equity acquisition consideration by the Company during the Reporting Period.
Treasury shares	1,124,475,008.61	300,069,890.00	274.74%	Mainly due to the repurchase of treasury shares by the Company during the Reporting Period.
Other comprehensive income	-81,317,118.25	57,068,522.37	-242.49%	Mainly due to differences in the currency translation difference of the Company resulting from foreign exchange rate fluctuations during the Reporting Period.

2. *Explanation of anomalies for income statement items and the reasons thereof*

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Investment income	29,328,488.54	440,220,795.12	-93.34%	Mainly due to the decrease in investment income from long-term equity investments accounted for using the equity method during the Reporting Period.
Gain from changes in fair value	-596,976,684.29	323,191,353.26	-284.71%	Mainly due to losses from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-3,489,082.08	-26,908,313.51	Not applicable	Mainly due to the decrease in bad debt provision for accounts receivable made by the Company during the Reporting Period.
Gain on disposal of assets	-16,069,206.08	5,223,121.86	-407.66%	Mainly due to losses incurred from the disposal of non-current assets by the Company during the Reporting Period.
Non-operating income	1,622,950.47	809,111.08	100.58%	Mainly due to the increase in government grants received by the Company during the Reporting Period.
Non-operating expenses	3,909,561.95	7,037,847.33	-44.45%	Mainly due to the decrease in expenses of donations by the Company during the Reporting Period.

3. Explanation of anomalies for cash flow statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Net cash flows from investing activities	-84,849,660.32	493,706,798.02	-117.19%	Mainly due to the decrease in redemption of the Company's wealth management products during the Reporting Period as compared to that in the corresponding period.
Net cash flows from financing activities	-338,418,546.73	-1,684,788,363.95	Not applicable	Mainly due to the increase in net cash inflow from borrowings less cash outflow for debt repayments during the Reporting Period.

II. SHAREHOLDERS' INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored and the shareholding of top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	46,128	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	0

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares	
					Share status	Quantity
Ye Xiaoping	Domestic natural person	20.58%	177,239,541	132,929,656	Not applicable	0
HKSCC Nominees Limited	Overseas legal person	14.30%	123,118,719	0	Not applicable	0
Cao Xiaochun	Domestic natural person	5.96%	51,314,174	38,739,300	Pledged	18,500,000
Hong Kong Securities Clearing Company Limited	Overseas legal person	3.56%	30,627,611	0	Not applicable	0
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	3.46%	29,771,136	0	Not applicable	0
China Everbright Bank Company Limited – Aegon-Industrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	Others	2.62%	22,543,933	0	Not applicable	0
China Merchants Bank Co., Ltd. – AIFMC Herun Hybrid Securities Investment Fund	Others	2.12%	18,276,980	0	Not applicable	0

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares	
					Share status	Quantity
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	Others	1.67%	14,386,342	0	Not applicable	0
Shi Xiaoli	Domestic natural person	1.05%	9,006,272	0	Pledged	1,358,283
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Drug Industry Trading Open-End Index Securities Investment Fund	Others	0.93%	8,018,750	0	Not applicable	0

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares held not subject to selling restrictions	Class and number of shares	
		Class of shares	Quantity
HKSCC Nominees Limited	123,118,719	Overseas listed foreign shares	123,118,719
Ye Xiaoping	44,309,885	Renminbi ordinary shares	44,309,885
Hong Kong Securities Clearing Company Limited	30,627,611	Renminbi ordinary shares	30,627,611
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	29,771,136	Renminbi ordinary shares	29,771,136
China Everbright Bank Company Limited – Aegon-Industrial Commercial Mode Preferred Hybrid Securities Investment Fund (LOF)	22,543,933	Renminbi ordinary shares	22,543,933
China Merchants Bank Co., Ltd. – AIFMC Herun Hybrid Securities Investment Fund	18,276,980	Renminbi ordinary shares	18,276,980
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	14,386,342	Renminbi ordinary shares	14,386,342
Cao Xiaochun	12,574,874	Renminbi ordinary shares	12,574,874

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares held not subject to selling restrictions	Class and number of shares	
		Class of shares	Quantity
Shi Xiaoli	9,006,272	Renminbi ordinary shares	9,006,272
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Drug Industry Trading Open-End Index Securities Investment Fund	8,018,750	Renminbi ordinary shares	8,018,750
Explanation of the shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.		
Description of top 10 shareholders participating in the margin trading business (if any)	Nil.		

As of September 30, 2026, the Company's repurchase-specific securities account held 26,847,258 A shares, or 3.12% of the total shares.

Shareholders holding 5% or more of the shares, the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions participating in lending shares through shares lending and refinancing business

☐Applicable ☑Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions compared with the previous period due to lending/returning shares through shares lending and refinancing

☐Applicable ☑Not applicable

(II) Total number of preferred shareholders of the Company and the shareholding of top 10 preferred shareholders

☐Applicable ☑Not applicable

(III) Changes in restricted shares

☑Applicable ☐Not applicable

Unit: share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares unlocked during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Cao Xiaochun	38,746,330	7,030	0	38,739,300	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Li Xiaori	11,058	0	0	11,058	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Total	171,687,044	7,030	0	171,680,014	–	–

III. OTHER SIGNIFICANT EVENTS

☑Applicable ☐Not applicable

1. On March 30, 2026 and June 2, 2026, the Company convened the 23rd meeting of the fifth session of the Board of Directors and the 2025 annual general meeting, respectively, at which the relevant resolutions regarding the re-election of the Board of Directors were considered and approved. Three executive Directors and three independent non-executive Directors were elected to the sixth session of the Board of Directors, who, together with one employee representative Director elected at the employee representative meeting convened by the Company, constitute the sixth session of the Board of Directors. To ensure the smooth operation of the Board of Directors, the Company convened the first meeting of the sixth session of the Board of Directors on the same day, at which it elected the members of the special committees and the Chairman of the sixth session of the Board of Directors, and appointed the new session of the Company's senior management. For details, please refer to the Company's relevant announcements published on cninfo.com.cn on March 31 and June 2, 2026.

2. On May 13, 2026 and June 9, 2026, the Company convened the 25th meeting of the fifth session of the Board of Directors, the 2026 second extraordinary general meeting, the second A share class meeting of 2026 and the second H share class meeting of 2026, respectively, at which the Resolution on Plan for the Repurchase of the Shares of the Company was considered and approved. Pursuant to the Share Repurchase plan, the Company intends to repurchase a portion of its A shares using its own funds or self-raised funds through centralized price bidding or other methods permitted by laws and regulations, for the subsequent implementation of equity incentive or employee stock ownership and cancellation to reduce its registered capital. The total amount of funds for the shares to be repurchased will be not less than RMB500 million and not more than RMB1,000 million; the repurchase price shall not exceed RMB60 per share. The specific amount of repurchase funds shall be subject to the actual amount upon completion of the implementation of the repurchase. The implementation period of the share repurchase shall be no more than 12 months from the date on which the Share Repurchase plan is considered and approved by the general meeting. As of the announcement date of this report, the Company has repurchased 20,963,478 of the Company's shares through the repurchase-specific securities account by way of centralized price bidding, representing 2.4347% of the Company's current total share capital and 2.8410% of the Company's current total A-share share capital. The highest trading price was RMB42.78 per share, the lowest trading price was RMB38.22 per share, and the total trading amount was RMB824,339,556.29 (excluding transaction expenses). For details, please refer to the Company's relevant announcements published on cninfo.com.cn on May 14 and August 3, 2026.

3. On August 28, 2026 and September 23, 2026, the Company convened the second meeting of the sixth session of the Board of Directors and the 2026 third extraordinary general meeting, respectively, at which the Resolution on the 2026 Restricted A Share Incentive Scheme and Its Summary, the Resolution on the Management Measures for Assessment Relating to the Implementation of the 2026 Restricted A Share Incentive Scheme and the Resolution on Authorisation to Handle Matters Pertaining to the 2026 Restricted A Share Incentive Scheme were considered and approved. On October 9, 2026, the Company convened the third meeting of the sixth session of the Board of Directors, at which the Resolution on Adjustment to the List of Participants and the Number of Restricted Shares Granted under the 2026 Restricted A Share Incentive Scheme and the Resolution on the Grant of Restricted Shares to Participants under the 2026 Restricted A Share Incentive Scheme were considered and approved. For details, please refer to the Company's relevant announcements published on cninfo.com.cn on August 29, 2026, September 23, 2026 and October 10, 2026.

4. On September 11, 2026 and October 16, 2026, Mr. Ye Xiaoping ("**Mr. Ye**") and Ms. Cao Xiaochun ("**Ms. Cao**") received the Decision on Imposing the Measure of Issuing a Warning Letter to Ye Xiaoping and Cao Xiaochun (《關於對葉小平、曹曉春採取出具警示函措施的決定》) (the "**Warning Letter**"), Advance Notice of Administrative Penalty (《行政處罰事先告知書》) Zhe Jiang (2026) No. 21 (the "**Notice**") and Decision of Administrative Penalty (《行政處罰決定書》) (2026) No. 38 (the "**Decision**") from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission (the "**Zhejiang Regulatory Bureau**"), respectively. On October 16, 2026, Mr. Ye and Ms. Cao also received the disciplinary determination of public criticism (Shen Zheng Shang (2026) No. 1389) (the "**Determination**") from the Shenzhen Stock Exchange ("**SZSE**"). The Warning Letter, Notice, Decision and Determination relate to information disclosure matters of historical changes in shareholdings in A shares of the Company. For details, please refer to the announcements of the Company dated May 12, 2026, September 11, 2026 and October 16, 2026.

   Upon receiving the Warning Letter, Notice, Decision and Determination, the Board (without the presence of Mr. Ye and Ms. Cao to avoid any potential conflict of interests) conducted a comprehensive evaluation of the nature, facts and circumstances behind the Warning Letter, Notice, Decision and Determination, and considers that notwithstanding the Warning Letter, Notice, Decision and Determination, Mr. Ye and Ms. Cao are still suitable to act as Directors under Rules 3.08 and 3.09 of the Listing Rules, for the reasons set out below:

   (a) to the best knowledge, information and belief of the Directors and as confirmed by Mr. Ye and Ms. Cao, the Warning Letter, Notice, Decision and Determination relate to an inadvertent oversight by Mr. Ye and Ms. Cao of information disclosure obligations of historical changes in shareholdings in A shares of the Company, such shareholding changes of which have already been disclosed subsequently in the Company's announcements and periodic reports. The Warning Letter, Notice, Decision and Determination did not involve any dishonest or fraudulent act nor did it indicate any issue of integrity or bad character on the part of Mr. Ye and Ms. Cao which would adversely affect Mr. Ye and Ms. Cao's suitability to act as Directors;

   (b) to the best knowledge, information and belief of the Directors and as confirmed by Mr. Ye and Ms. Cao, save for the incidents giving rise to Warning Letter, Notice, Decision and Determination, Mr. Ye and Ms. Cao have no previous record of any other administrative penalties imposed by the CSRC and other regulatory authorities in the PRC (including Hong Kong);

(c) to the best knowledge, information and belief of the directors, the Warning Letter, Notice, Decision and Determination do not disqualify Mr. Ye and Ms. Cao from acting as Directors under the Securities Law of the People's Republic of China as amended in 2019, SZSE listing rules, or other relevant PRC laws;

(d) both Mr. Ye and Ms. Cao have participated in relevant training in relation to the statutory obligations of directors and insider disclosure requirements and will continue to keep abreast of the latest regulatory developments, in accordance with Rules 3.09F and 3.09G of Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and

(e) both Mr. Ye and Ms. Cao have extensive industry experience and have competently discharged their duties as Directors since their appointment. They are familiar with the Company's business operations and play a key role in the Company's development and business expansion. The Directors consider that their professional knowledge, skills and experience will bring valuable insight and benefits to the Board and the Company. Save for the incidents giving rise to the Warning Letter, Notice, Decision and Determination, Mr. Ye and Ms. Cao are responsible and competent members of the Board who act honestly and in good faith in the interests of the Company as a whole and for a proper purpose.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

September 30, 2026

Unit: RMB

Item	Closing balance	Opening balance
Current assets:		
Cash at bank and on hand	2,102,880,276.00	1,777,491,807.26
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	15,454,600.36	59,459,161.12
Derivative financial assets		
Notes receivable	5,440,896.92	7,004,266.15
Accounts receivable	1,423,815,415.67	1,405,728,258.63
Receivables financing	816,415.29	3,953,348.43
Advances to suppliers	182,020,443.18	122,972,634.86
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	118,443,336.33	109,395,716.23
Including: Interests receivable		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	62,996,166.23	41,501,796.41
Including: Data resources		
Contract assets	2,730,653,878.93	2,584,975,822.49
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	194,103,189.19	64,713,930.31
Total current assets	6,836,624,618.10	6,177,196,741.89

Item	Closing balance	Opening balance
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	4,624,765,397.41	4,498,839,308.43
Other equity instruments investment	6,617,892.86	8,545,553.12
Other non-current financial assets	9,698,181,719.69	9,840,237,126.48
Investment properties	15,563,627.27	15,388,440.06
Fixed assets	1,157,233,461.02	1,188,210,085.11
Construction in progress	77,932,306.75	110,604,207.57
Productive biological assets		
Oil and gas assets		
Right-of-use assets	332,225,909.08	408,905,731.66
Intangible assets	220,821,074.59	276,312,305.22
Including: Data resources		
Development disbursements		
Including: Data resources		
Goodwill	3,457,049,465.57	3,520,215,745.68
Long-term deferred expenses	174,598,965.04	189,282,477.31
Deferred tax assets	152,833,193.31	145,119,832.23
Other non-current assets	1,231,367,406.27	1,979,937,603.41
Total non-current assets	21,149,190,418.86	22,181,598,416.28
Total assets	27,985,815,036.96	28,358,795,158.17

Item	Closing balance	Opening balance
Current liabilities:		
Short-term borrowings	265,266,196.31	511,020,767.84
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable	3,239,727.72	5,889,386.05
Accounts payable	334,229,084.31	365,228,858.73
Advanced receipts		
Contract liabilities	1,436,359,968.22	1,079,154,504.24
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	302,566,079.19	327,858,233.53
Tax payable	112,447,498.78	231,541,815.12
Other payables	66,659,389.67	74,461,840.09
Including: Interests payable	451,840.14	1,388,432.36
Dividends payable	226,842.10	3,752,582.61
Fees and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	121,268,436.22	201,525,360.57
Other current liabilities	46,311,602.55	38,793,286.00
Total current liabilities	2,688,347,982.97	2,835,474,052.17

Item	Closing balance	Opening balance
Non-current liabilities:		
Reserves for insurance contract		
Long-term borrowings	1,423,866,310.52	510,560,589.95
Bonds payable	101,915,495.55	92,473,704.64
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	305,468,348.86	360,616,779.32
Long-term payables	11,980,000.00	102,518,850.00
Long-term employee benefits payable	10,313,395.72	10,897,307.43
Provisions		
Deferred revenue	15,036,273.86	16,408,677.01
Deferred tax liabilities	167,591,399.58	173,420,006.70
Other non-current liabilities		
Total non-current liabilities	2,036,171,224.09	1,266,895,915.05
Total liabilities	4,724,519,207.06	4,102,369,967.22
Owners' equity:		
Share capital	861,026,050.00	861,026,050.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital surplus	10,603,057,808.88	10,584,957,589.83
Less: Treasury shares	1,124,475,008.61	300,069,890.00
Other comprehensive income	-81,317,118.25	57,068,522.37
Special reserve		
Surplus reserve	436,529,393.76	436,529,393.76
General risk provision		
Retained earnings	8,942,879,242.17	9,319,994,848.81
Total equity attributable to owners of the parent	19,637,700,367.95	20,959,506,514.77
Non-controlling interests	3,623,595,461.95	3,296,918,676.18
Total owners' equity	23,261,295,829.90	24,256,425,190.95
Total liabilities and owners' equity	27,985,815,036.96	28,358,795,158.17

Legal representative: **Wen Zengyu** *Person-in-charge of accounting affairs:* **Yang Chengcheng** *Head of accounting department:* **Chen Xiaocui**

2. *Consolidated income statement from the beginning of the year to the end of the Reporting Period*

Unit: RMB

Item			Amount for the Reporting Period	Amount for the prior period
I.	Total operating revenue		5,791,528,067.34	5,025,868,260.75
	Including:	Operating revenue	5,791,528,067.34	5,025,868,260.75
		Interest income		
		Premium earned		
		Fees and commission income		
II.	Total operating costs		5,216,682,770.59	4,559,527,495.20
	Including:	Operating costs	4,207,600,108.35	3,560,252,024.84
		Interest expenses		
		Fees and commission expenses		
		Cash surrender value		
		Claim settlement expenses, net		
		Net provision of insurance contract liabilities		
		Policy dividend expense		
		Reinsurance expenses		
		Taxes and surcharges	28,542,226.50	25,585,746.05
		Selling expenses	174,154,972.01	175,449,787.82
		General and administrative expenses	534,025,131.59	530,840,458.53
		Research and development expenses	206,608,033.85	191,239,953.92
		Finance expenses	65,752,298.29	76,159,524.04
		Including: Interest expenses		
		Interest income		
	Add:	Other income	29,722,892.85	26,343,546.96
		Investment income (losses are expressed by "-")	29,328,488.54	440,220,795.12
		Including: Income from investment in associates and joint ventures		
		Gain on de-recognition of financial assets at amortized cost		
		Foreign exchange gain (losses are expressed by "-")		
		Net exposure hedging gain (losses are expressed by "-")		
		Gain from changes in fair values (losses are expressed by "-")	-596,976,684.29	323,191,353.26
		Credit impairment loss (losses are expressed by "-")	-3,489,082.08	-26,908,313.51
		Asset impairment loss (losses are expressed by "-")	-5,174,622.28	-5,401,777.73
		Gain on disposal of assets (losses are expressed by "-")	-16,069,206.08	5,223,121.86

Item	Amount for the Reporting Period	Amount for the prior period
III. Operating Profit (losses are expressed by "-")	12,187,083.41	1,229,009,491.51
Add: Non-operating income	1,622,950.47	809,111.08
Less: Non-operating expenses	3,909,561.95	7,037,847.33
IV. Total Profit (total losses are expressed by "-")	9,900,471.93	1,222,780,755.26
Less: Income tax expenses	133,953,129.29	131,099,588.80
V. Net Profit (net losses are expressed by "-")	-124,052,657.36	1,091,681,166.46
(I) Classified by continuing operations		
1. Net profit from continuing operations (net losses are expressed by "-")	-124,052,657.36	1,091,681,166.46
2. Net profit from discontinued operations (net losses are expressed by "-")		
(II) Classified by ownership of equity		
1. Net profits attributable to shareholders of the parent (net losses are expressed by "-")	-272,048,633.37	1,020,434,157.81
2. Non-controlling gain or loss (net losses are expressed by "-")	147,995,976.01	71,247,008.65
VI. Other comprehensive income, net of tax	-172,607,574.25	9,646,423.79
Other comprehensive income attributable to owners of the parent, net of tax	-138,385,640.62	8,770,477.73
(I) Items that will not be reclassified subsequently to profit or loss	-1,013,387.61	444,801.15
1. Changes arising from re-measurement of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss		
3. Change in fair value of other equity instruments investment	-1,013,387.61	444,801.15
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the Reporting Period	Amount for the prior period
(II) Items that may be reclassified to profit or loss	-137,372,253.01	8,325,676.58
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investments		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investments		
5. Cash flow hedge reserve		
6. Currency translation difference	-137,372,253.01	8,325,676.58
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	-34,221,933.63	875,946.06
VII. Total comprehensive income	-296,660,231.61	1,101,327,590.25
(I) Total comprehensive income attributable to owners of the parent	-410,434,273.99	1,029,204,635.54
(II) Total comprehensive income attributable to non-controlling interests	113,774,042.38	72,122,954.71
VIII. Earnings per share:		
(I) Basic earnings per share	-0.32	1.19
(II) Diluted earnings per share	-0.32	1.19

For the business combination under common control in the current period, the net profit realized by the acquiree before the combination was nil, and the net profit realized by the acquiree in the prior period was nil.

Legal representative:	*Person-in-charge of accounting affairs:*	*Head of accounting department:*
Wen Zengyu	**Yang Chengcheng**	**Chen Xiaocui**

3. Consolidated cash flow statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item		Amount for the Reporting Period	Amount for the prior period
I.	Cash flows from operating activities:		
	Cash received from sale of goods or rendering of services	6,306,144,935.69	5,317,979,333.00
	Net increase in customer deposits and placements from other banks		
	Net increase in due to central bank		
	Net increase in borrowings from other financial institutions		
	Cash from premiums on original insurance contracts		
	Cash received from reinsurance business, net		
	Net increase in insured's deposits and investments		
	Cash received from interest, fees and commissions		
	Net increase in placements from banks and other financial institutions		
	Net increase of funds in repurchase business		
	Net cash received from customer brokerage		
	Tax refunds	17,484,419.63	14,560,502.32
	Cash receipts related to other operating activities	111,266,621.31	81,749,437.45
	Sub-total of cash inflows from operating activities	6,434,895,976.63	5,414,289,272.77
	Cash paid for goods and services	2,052,754,376.60	1,592,666,205.03
	Net increase in loans and advances to customers		
	Net increase in deposits with central bank and other banks		
	Cash paid for claim settlements on original insurance contracts		
	Net increase in placements with banks and other financial institutions		
	Cash paid for interest, fees and commissions		
	Cash paid for policy dividends		
	Cash paid to and on behalf of employees	2,672,917,939.44	2,363,815,844.10
	Payments of all types of taxes	448,166,533.31	320,605,174.81
	Cash payments related to other operating activities	489,745,203.83	397,644,419.26
	Sub-total of cash outflows from operating activities	5,663,584,053.18	4,674,731,643.20
	Net cash flows from operating activities	771,311,923.45	739,557,629.57

Item		Amount for the Reporting Period	Amount for the prior period
II.	Cash flows from investing activities:		
	Cash received from sale of investments	1,415,438,668.24	1,777,634,145.31
	Cash receipts from returns on investments	334,203,700.27	165,736,772.10
	Net cash received from disposal of fixed assets, intangible assets and other long-term assets	651,986.93	2,139,573.13
	Net cash received from disposal of subsidiaries and other business units		
	Cash receipts related to other investing activities	41,000,000.00	17,128,630.27
	Sub-total of cash inflows from investing activities	1,791,294,355.44	1,962,639,120.81
	Cash paid to acquire fixed assets, intangible assets and other long-term assets	131,139,268.95	173,581,867.91
	Cash paid for investments	1,738,352,529.11	1,138,161,366.31
	Net increase in pledged loans		
	Net cash paid for acquisition of subsidiaries and other business units	400,000.00	115,646,821.75
	Cash payments related to other investing activities	6,252,217.70	41,542,266.82
	Sub-total of cash outflows from investing activities	1,876,144,015.76	1,468,932,322.79
	Net cash flows from investing activities	-84,849,660.32	493,706,798.02
III.	Cash flows from financing activities:		
	Cash receipts from capital contributions	223,050,000.00	162,098,000.00
	Including: Cash receipts from capital contributions from non-controlling interests of subsidiaries		
	Cash received from borrowings	1,213,764,354.77	1,044,986,871.59
	Cash receipts related to other financing activities	16,295,140.68	61,200,000.00
	Sub-total of cash inflows from financing activities	1,453,109,495.45	1,268,284,871.59
	Cash repayments for debts	587,019,853.36	2,170,230,969.65
	Cash payments for distribution of dividends, profits or interest expenses	192,199,533.47	341,108,089.30
	Including: Dividends and profits paid to non-controlling interests by subsidiaries		
	Cash payments related to other financing activities	1,012,308,655.35	441,734,176.59
	Sub-total of cash outflows from financing activities	1,791,528,042.18	2,953,073,235.54
	Net cash flows from financing activities	-338,418,546.73	-1,684,788,363.95
IV.	Effect of change in foreign exchange rates on cash and cash equivalents	-30,244,682.58	2,935,487.08
V.	Net increase in cash and cash equivalents	317,799,033.82	-448,588,449.28
	Add: Cash and cash equivalents at the beginning of the period	1,722,608,377.68	2,048,493,852.84
VI.	Cash and cash equivalents at the end of the period	2,040,407,411.50	1,599,905,403.56

(II) Particulars in relation to adjustments made to the financial statements as at the beginning of the year of the initial adoption of new accounting standards since 2026

☐Applicable ☑Not applicable

(III) Audit Report

Whether the third-quarter financial and accounting report is audited

☐Yes ☑No

The third-quarter financial and accounting report of the Company is unaudited.

The Board of Directors of Hangzhou Tigermed Consulting Co., Ltd.
October 29, 2026